Hadassah

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Wednesday, Dec 17 2014

A new drug technology, developed at the Hadassah Medical Organization to treat fatty liver disease--a condition with no approved effective drug treatment--was given the go-ahead by the United States Food and Drug Administration (FDA) for a Phase 2 multi-center clinical trial in the US.

In its severe form (called nonalcoholic steatohepatitis-NASH), fatty liver disease can lead to cirrhosis and liver cancer. Current estimates reveal that at least five percent of the Western world’s population suffers from the disease. The majority of these patients also have diabetes, high blood lipids, and obesity.

The new technology was developed by Prof. Yaron Ilan, Director, Department of Internal Medicine and former president of the Israel Liver Association, and his team in Hadassah’s Liver Unit. Based on feeding natural antibodies against intestinal bacteria associated with fatty liver disease, the treatment reduces inflammation by directly affecting the activity level of regulatory T cells in the liver and fat tissues. “The new drug is based on a novel discovery that bacteria in our gut are relevant for the induction of inflammation in our body, which is associated with liver disease, diabetes, and obesity” said Prof. Ilan. “The new therapy is safe and has no side effect, and we hope the results of the phase II trial will enable us to move forward with its development as a treatment for diabetes and fatty liver disease”.

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron.

The multi-center clinical trial will involve 120 patients in several leading medical centers in the US and Australia. The cohort will receive the treatment for six months, while monitored for the state of their liver disease, diabetes, and lipid profile.

Clinical trials were already conducted at Hadassah, which confirmed the safety and efficacy of the treatment.

Read about the 2009 discovery of treatment for fatty liver disease

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Dec 7 2016

Saturday Night Lively: Hadassah Israel Fundraiser Wows Largely Orthodox Audience of 1200

Hadassah International Israel (HII) drew over 1200 men and women to a concert at Tel Aviv University, targeting the funds raised for renovation of the rehabilitation facilities at Hadassah Hospital Mount Scopus.

READ MORE ›
alt_text

Monday, Dec 5 2016

Celebrated Israeli Psychiatrist/Neurobiologist To Join Hadassah Medical Staff

Prof. Yoram Yovell, renowned Israeli psychiatrist and neurobiologist, will soon be joining the Hadassah Medical Organization’s “brain medicine branch,” which includes the departments of psychiatry, neurology, and neurosurgery and is under the direction of Prof. Tamir Ben-Hur.

READ MORE ›
alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›
alt_text

Thursday, Nov 17 2016

Ethiopian Pre-Nursing Students: On the Way to Fulfilling a Dream

“I know that some people are fine with looking at a screen all day, but I know I need the human touch--to work with people. I want to be a nurse, " relates Sarah Talala, one of the 18 students of Ethiopian background who were given the opportunity to take a course which enabled them to advance to pre-academic studies at the Hebrew University and then on to nursing school at the Hadassah-Hebrew University Henrietta Szold School of Nursing.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More